Sylentis announced that SYL1801, an investigational siRNA therapy administered as eye drops, met its primary endpoint in a Phase IIa study for neovascular age-related macular degeneration (nAMD).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.